相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Preoperative Delays in the Treatment of DCIS and the Associated Incidence of Invasive Breast Cancer
William H. Ward et al.
ANNALS OF SURGICAL ONCOLOGY (2020)
Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance)
E. Shelley Hwang et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future
Laura M Spring et al.
LANCET (2020)
Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study
Hiroji Iwata et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial
Shu-Lian Wang et al.
LANCET ONCOLOGY (2019)
Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study
Sara A. Hurvitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial
Helena M. Earl et al.
LANCET (2019)
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial
Xavier Pivot et al.
LANCET (2019)
Symptom palliation of hypofractionated radiotherapy for patients with incurable inflammatory breast cancer
Hoon Sik Choi et al.
RADIATION ONCOLOGY (2019)
Lessons Learned From Hurricane Maria in Puerto Rico: Practical Measures to Mitigate the Impact of a Catastrophic Natural Disaster on Radiation Oncology Patients
Hiram A. Gay et al.
PRACTICAL RADIATION ONCOLOGY (2019)
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
G. von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Predictors of Residual Disease After Breast Conservation Surgery
Lisa J. Findlay-Shirras et al.
ANNALS OF SURGICAL ONCOLOGY (2018)
Clinical impact of adjuvant radiation therapy delay after neoadjuvant chemotherapy in locally advanced breast cancer
Saulo Brito Silva et al.
BREAST (2018)
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
J. A. Sparano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Breast Cancer Screening in Women at Higher-Than-Average Risk: Recommendations From the ACR
Debra L. Monticciolo et al.
JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY (2018)
Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial
Ulrike Nitz et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
Retrospective analysis of HER2 therapy interruption in patients responding to the treatment in metastatic HER2+ breast cancer
Tiina Moilanen et al.
ESMO OPEN (2017)
Impact of Time from Completion of Neoadjuvant Chemotherapy to Surgery on Survival Outcomes in Breast Cancer Patients
Rachel A. Sanford et al.
ANNALS OF SURGICAL ONCOLOGY (2016)
Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial
A. Murray Brunt et al.
RADIOTHERAPY AND ONCOLOGY (2016)
Time to Surgery and Breast Cancer Survival in the United States
Richard J. Bleicher et al.
JAMA ONCOLOGY (2016)
Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer A Systematic Review and Meta-analysis
Laura M. Spring et al.
JAMA ONCOLOGY (2016)
Addressing overtreatment of screen detected DCIS; the LORIS trial
Adele Francis et al.
EUROPEAN JOURNAL OF CANCER (2015)
Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD study
Lotte E. Elshof et al.
EUROPEAN JOURNAL OF CANCER (2015)
Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)
William M. Sikov et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial
Ian H. Kunkler et al.
LANCET ONCOLOGY (2015)
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial
Jack Cuzick et al.
LANCET (2014)
Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343
Kevin S. Hughes et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials
Joanne S. Haviland et al.
LANCET ONCOLOGY (2013)
Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial
Norikazu Masuda et al.
LANCET ONCOLOGY (2012)
Monthly versus 3-monthly goserelin acetate treatment in pre-menopausal patients with estrogen receptor-positive early breast cancer
Norikazu Masuda et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015)
John R. Yarnold et al.
RADIOTHERAPY AND ONCOLOGY (2011)
Long-Term Results of Hypofractionated Radiation Therapy for Breast Cancer
Timothy J. Whelan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Intervals Longer Than 20 Weeks From Breast-Conserving Surgery to Radiation Therapy Are Associated With Inferior Outcome for Women With Early-Stage Breast Cancer Who Are Not Receiving Chemotherapy
Ivo A. Olivotto et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Impact of Pathological Characteristics on Local Relapse After Breast-Conserving Therapy: A Subgroup Analysis of the EORTC Boost Versus No Boost Trial
Heather A. Jones et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Palliative radiotherapy trials for bone metastases: A systematic review
Edward Chow et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Randomized trial of short-versus long-course radiotherapy for palliation of painful bone metastases
WF Hartsell et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: Updated results of a prospective randomized trial
JR Bellon et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Magnetic resonance imaging of the breast prior to biopsy
DA Bluemke et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Late follow-up of a randomized trial of surgery plus tamoxifen versus tamoxifen alone in women aged over 70 years with operable breast cancer
M Fennessy et al.
BRITISH JOURNAL OF SURGERY (2004)
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of intergroup trial C9741/cancer and leukemia group B trial 9741
ML Citron et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Tamoxifen alone versus adjuvant tamoxifen or operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial
G Mustacchi et al.
ANNALS OF ONCOLOGY (2003)
分享论文
